by Francisca Peixoto | Jul 23, 2025 | Uncategorized
Our portfolio company, Eveliqure Biotechnologies, has begun dosing participants in a Phase 2b clinical trial of its oral ShigETEC vaccine. Eveliqure Biotechnologies has begun dosing participants in a Phase 2b clinical trial of its oral ShigETEC vaccine, designed to...
by Francisca Peixoto | May 8, 2025 | Uncategorized
We are excited to announce another exciting addition to LifeLink’s portfolio, HAYA Therapeutics. We’re very proud to have joined the $65 million Series A financing round, led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli...
by Francisca Peixoto | Apr 1, 2025 | Uncategorized
Our portfolio company, AIRNA, has secured an oversubscribed $155 million Series B financing round to advance its lead RNA-editing therapeutic, AIR-001, into Phase 1/2 clinical trials for alpha-1 antitrypsin deficiency (AATD). AATD is a genetic condition caused by...
by Francisca Peixoto | Feb 5, 2025 | Uncategorized
Recently, our portfolio company Accure Therapeutics announced the successful results of the ACUITY phase 2 trial in collaboration with Oculis. Accure Therapeutics, a pioneering translational neuroscience R&D company, has made significant strides in the field of...
by Francisca Peixoto | Oct 8, 2024 | Uncategorized
We are excited to announce another exciting addition to LifeLink’s portfolio. Arda Therapeutics $43M Series A was led by Andreessen Horowitz (a16z) Bio with participation from Eli Lilly and Company Ventures, GV (Google Ventures), Two Sigma Ventures, RV Invest,...
